Health & Science Correspondent
Story audio is generated using AI
It will be the first registered alternative to Ozempic available to consumers, as only one generic rival has so far been approved by South Africa’s medicines authority, and it has yet to hit the market.
The scale of the price drop is likely to disappoint many patients, as it does not appear large enough to prompt medical schemes to expand coverage.
Medical scheme administrator Discovery Health, which typically leads the industry on decisions about coverage for costly new treatments, said there are no immediate plans to change the eligibility criteria for members of its biggest client, Discovery Health Medical Scheme (DHMS).
